Compare ALGM & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALGM | EXEL |
|---|---|---|
| Founded | 1990 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8B | 11.4B |
| IPO Year | 2007 | 2000 |
| Metric | ALGM | EXEL |
|---|---|---|
| Price | $54.48 | $54.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 21 |
| Target Price | $44.27 | ★ $46.50 |
| AVG Volume (30 Days) | ★ 3.3M | 2.4M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.49 | 57.95 |
| EPS | N/A | ★ 0.79 |
| Revenue | ★ $890,096,000.00 | $452,477,000.00 |
| Revenue This Year | $24.20 | $13.61 |
| Revenue Next Year | $17.94 | $13.13 |
| P/E Ratio | ★ N/A | $70.66 |
| Revenue Growth | ★ 22.77 | N/A |
| 52 Week Low | $22.41 | $33.76 |
| 52 Week High | $71.77 | $56.21 |
| Indicator | ALGM | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 52.41 | 67.16 |
| Support Level | $26.99 | $40.17 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 4.97 | 1.57 |
| MACD | 0.45 | 0.11 |
| Stochastic Oscillator | 40.81 | 93.35 |
Allegro Microsystems Inc is a designer, developer, fabless manufacturer, and marketer of sensor ICs and application-specific analog power ICs for automotive and industrial markets. Its Sensor IC allows customers to precisely measure motion, speed, position, and current, and Power ICs include high-temperature and high-voltage capable motor drivers, power management, and LED driver ICs. Its products are divided into three categories: SENSE, which includes Current Sensors, Switches, and Latches, and Interface ICs among others; REGULATE, which includes Regulators, ClearPower Modules, and LED Drivers; and DRIVE, which includes BLDC Drivers, Brush DC, and others. Product-wise, the firm derives the majority of its revenue from sales of Magnetic sensors.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.